Suppr超能文献

用于治疗脓毒症、哮喘和特应性皮炎等炎症性疾病的重新定位药物。

Repositioned Drugs for Inflammatory Diseases such as Sepsis, Asthma, and Atopic Dermatitis.

作者信息

Prakash Annamneedi Venkata, Park Jun Woo, Seong Ju-Won, Kang Tae Jin

机构信息

Convergence Research Center, Department of Pharmacy and Institute of Chronic Disease, Sahmyook University, Seoul 01795, Republic of Korea.

出版信息

Biomol Ther (Seoul). 2020 May 1;28(3):222-229. doi: 10.4062/biomolther.2020.001.

Abstract

The process of drug discovery and drug development consumes billions of dollars to bring a new drug to the market. Drug development is time consuming and sometimes, the failure rates are high. Thus, the pharmaceutical industry is looking for a better option for new drug discovery. Drug repositioning is a good alternative technology that has demonstrated many advantages over drug development, the most important one being shorter drug development timelines. In the last two decades, drug repositioning has made tremendous impact on drug development technologies. In this review, we focus on the recent advances in drug repositioning technologies and discuss the repositioned drugs used for inflammatory diseases such as sepsis, asthma, and atopic dermatitis.

摘要

药物发现和药物开发过程耗费数十亿美元才能将一种新药推向市场。药物开发耗时且有时失败率很高。因此,制药行业正在寻找更好的新药发现选择。药物重新定位是一种很好的替代技术,已证明比药物开发具有许多优势,其中最重要的是缩短药物开发时间线。在过去二十年中,药物重新定位对药物开发技术产生了巨大影响。在本综述中,我们重点关注药物重新定位技术的最新进展,并讨论用于治疗脓毒症、哮喘和特应性皮炎等炎症性疾病的重新定位药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4548/7216745/b14a46d1df14/BT-28-222-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验